Fundraising FoxLiquidia Technologies
NASDAQ: LQDAMorrisville, US · Delaware corporation · 2 known investors
Find your way into Liquidia Technologies
67 people in our graph share verified history with the Liquidia Technologies team — schools, employers, funds. One of them is your warm intro.
Liquidia Technologies is a biopharmaceutical company that develops and commercializes drugs for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including YUTREPIA, an inhaled dry-powder treprostinil formulation, and treprostinil injection through a profit-sharing arrangement with Sandoz, along with pipeline candidates based on its PRINT particle-engineering platform.
Founders & leadership
Board
Investors · 2
How we know: Pappas Capital's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$47.9M disclosed across 2 rounds · 2018–2019
▶$22.4MraisedJan 2020 · 8 investors · BiotechnologyRule 506(b)
- RAMAN SINGHDirector
- ROBERT LIPPEExecutive Officer
- ARTHUR KIRSCHDirector
- RALPH SNYDERMANDirector
- KATHERINE RIELLY-GAUVINDirector
- JOANNA HOROBINDirector
- STEPHEN BLOCHDirector
- SETH A RUDNICKDirector
- FLORINA GORDON-KRAWCHICKExecutive Officer
- ROBERT ROSCIGNOExecutive Officer
- RICHARD D KATZExecutive Officer
- BENJAMIN MAYNORExecutive Officer
- JERI THOMASExecutive Officer
- NEAL F FOWLERExecutive Officer, Director
- Offering amount
- $22.4M
- Amount sold
- $22.4M
- Sales commissions
- $1.3M
- Placement agents
- JEFFERIES LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.5MraisedFeb 2018 · 7 investors · BiotechnologyRule 506(b)
- Kevin GordonExecutive Officer
- Stephen BlochDirector
- Raman SinghDirector
- Seth A. RudnickDirector
- Robert LippeExecutive Officer
- Jason RushtonDirector
- Isaac ChengDirector
- Benjamin MaynorExecutive Officer
- Ralph SnydermanDirector
- Timothy AlburyExecutive Officer
- Neal F. FowlerExecutive Officer, Director
- Arthur S. KirschDirector
- Robert RoscignoExecutive Officer
- Edward MathersDirector
- Offering amount
- $53.3M
- Amount sold
- $25.5M
- Minimum investment
- $1
- Finders' fees
- $400K
- Placement agents
- Healthios Capital Markets, LLC
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Liquidia Technologies mafia →6 people who came through Liquidia Technologies went on to found or lead other companies.
Frequently asked questions
- What does Liquidia Technologies do?
- Liquidia Technologies is a biopharmaceutical company that develops and commercializes drugs for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including YUTREPIA, an inhaled dry-powder treprostinil formulation, and treprostinil injection through a profit-sharing arrangement with Sandoz, along with pipeline candidates based on its PRINT particle-engineering platform.
- Who are Liquidia Technologies's investors?
- Liquidia Technologies's investors include Pappas Capital, Canaan Partners.
- How much funding has Liquidia Technologies raised?
- Liquidia Technologies has disclosed $47.9M raised across 2 rounds.
- Where is Liquidia Technologies headquartered?
- Liquidia Technologies is headquartered in Morrisville, US.